Global adult vaccines market growth is driven by increasing investments by governments and private firms in adult vaccination programs. Adult vaccinations have gained popularity as these protect vulnerable groups from serious diseases and infections. Growing awareness about available vaccines and their benefits for adults has prompted more individuals to get vaccinated. Moreover, expansion of indications for existing adult vaccines and development of new formulations have strengthened prevention against various diseases affecting the adult population worldwide. However, high development costs and lack of adequate vaccination infrastructure in developing nations can hamper the market growth.

Market Dynamics:

Global adult vaccines market growth is driven by rising prevalence of diseases such as influenza, meningococcal meningitis, pneumococcal infection, and others among adults. According to the World Health Organization, seasonal influenza  results in severe illness in around 3-5 million cases and 290,000-650,000 respiratory deaths globally every year. Increasing healthcare expenditures, favorable government support through vaccination programs and introduction of novel vaccines can drive the market growth. However, low awareness in developing countries, high R&D costs associated with development of new vaccines and storage requirements can hamper the market growth. Development of thermostable vaccines without refrigeration needs and combined adult vaccine formulations can offer opportunities for market players.

Key Features of the Study:

• This report provides in-depth analysis of the global adult vaccines market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2024–2031), considering 2023 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global adult vaccines market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include GlaxoSmithKline, Sanofi Pasteur, Merck, Novavax, Pfizer, and CSL Limited
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• Global adult vaccines market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global adult vaccines market

Detailed Segmentation-

• By Vaccines
  
  • Influenza 
  • Tetanus, Diphtheria, Pertussis (Td/Tdap) 
  • Varicella 
  • Human Papillomavirus 
  • Zoster 
  • Measles, Mumps, Rubella (MMR) 
  • Pneumococcal 
  • Hepatitis 
  • Others
• By Vaccine Type
  
  • Monovalent 
  • Multivalent   
• By Technology
  • Live Attenuated Vaccines
  • Inactivated Viral/Bacterial Vaccines
  • Toxoid Vaccines
  • Recombinant Vaccines
  • Conjugate Vaccines
•  By Region:        
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East
  • Africa
• Company Profiles:
  • GlaxoSmithKline plc
  • Merck & Co., Inc.
  • Pfizer Inc.
  • Sanofi Pasteur
  • AstraZeneca
  • Johnson & Johnson
  • Novavax, Inc.
  • Moderna, Inc.
  • Inovio Pharmaceuticals, Inc.
  • Bavarian Nordic
  • Dynavax Technologies Corporation
  • BioNTech S
  • Emergent BioSolutions Inc.
  • Serum Institute of India Pvt. Ltd.
  • Bharat Biotech
  • Sinovac Biotech Ltd.